Prot #INCB18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Project: Research project

Project Details

StatusFinished
Effective start/end date11/28/1811/28/24

Funding

  • PAREXEL International Corporation ((OE) Prot #INCB 18424-MA-GD-301 // (OE) Prot #INCB 18424-MA-G...)
  • Incyte Corporation ((OE) Prot #INCB 18424-MA-GD-301 // (OE) Prot #INCB 18424-MA-G...)